The best regulatory intelligence software for pharma in 2026

There's a reason Cortellis is the incumbent in so many buildings. The breadth is real, the alerting works, and a global team gets one contract spanning regulatory plus pipeline, deals, IP, and CMC-adjacent modules. For coverage insurance across dozens of jurisdictions, it does the job it was built for.

The limit is scale and traceability. Clarivate publishes 300k+ source documents alongside 2,000+ expert summaries, and they now ship an AI assistant that returns cited answers, so "they don't have primary documents" would be wrong. What differs is how much record sits underneath the question and how precisely a citation lands: hundreds of thousands of documents is a curated selection of the record, not the record, and a citation that lands on a document still leaves your SME hunting for the passage that supports the claim. That's why buyers with access still describe the strategy analysis getting redone by their own SMEs. Pricing is custom quote with startup plus annual fees buyers describe as substantial.

Its strength is reach: regulatory requirements for drugs, biologics, devices and IVDs across 110+ countries, regions, and international organizations — more geographies than anything else here, including us. Add cross-country comparison tables, alerting when a matching document changes, local expert summaries, and the ability to file your own internal documents alongside, and for global requirement tracking it does a job we don't attempt.

The limit is what a requirements library can't do: tell you the right course of action. It holds what's required. What it doesn't hold is the summary basis of approval packages, discipline reviews, trial protocols, or the published literature that show how an authority actually applied a requirement to a program like yours. So the catalog gives your RA team the rule and leaves them to supply the judgment, unaided, on what to actually do with it, which is precisely the part where they'd most like evidence behind their reasoning. It's also a search-and-filter surface: you still assemble the answer yourself, and users running AI-native tools alongside it report reaching for the newer tool first.

The most underacknowledged tool in the pharma stack: your organization has rolled a general assistant out to thousands of people, and some of them are asking it regulatory questions today. It's good at drafting, decent at orientation, and free at the margin.

It's also structurally unable to meet the citation bar, and the reason isn't fixable with better prompting. General models answer from memory plus the open web, weighted roughly evenly across blogs, trade press, and SEO content, because the authority databases that decide these questions are largely invisible to a crawler. Their economics assume a fast answer, so exhaustive reading is off the table. Copilot's version is narrower and more specific: grounded in your tenant, it returns your own documents when the question is about the outside world. Useful for internal knowledge, wrong for precedent.

The productive move is the one your IT department will also prefer: don't add a fourth AI interface. Connect Rhizome to the assistant you've already deployed, over MCP.

Large pharma is the one segment that genuinely can build this: there are platform teams, data engineers, and a mandate. The demo works, and the first version impresses.

What follows is the part that doesn't fit a roadmap: OCR pipelines for scanned filings, weekly refresh across dozens of authorities, an evaluation harness proving the agent didn't quietly answer from memory, and citation UX good enough that an SME trusts it. That's a product team's permanent job. And strategically, build AI where it differentiates you. A model that predicts whether a candidate works is core IP. Almost nobody differentiates on regulatory, so pointing scarce AI staff at the public record is hard to justify against the internal-data work only you can do.